Enhanced Affinity for Arachidonic Acid in Platelet-Rich Plasma from Rats with Adriamycin-Induced Nephrotic Syndrome

Summary

We have measured the response to arachidonic acid (AA) in platelet-rich plasma (PRP) of rats with Adriamycin-induced nephrotic syndrome. For this purpose we measured the kinetics of generation of malondialdehyde (MDA), a stable product of cyclooxygenase activity, in response to platelet stimulation with different concentrations of the substrate. The apparent K_m of platelet cyclo-oxygenase for AA was similar in PRP from control rats and rats treated 1–5 days previously, whereas it was significantly reduced, as compared to controls, in PRP of rats treated 2–5 weeks previously. Such a difference was not observed when washed platelet suspensions were tested instead of PRP. Experiments with crossed platelet/plasma systems indicated that in rats treated from 2–5 weeks, a plasmatic abnormality was indeed responsible for the increased affinity of platelets for AA.

It is conceivable that in this nephrotic syndrome model characterized by heavy proteinuria, some plasmatic component would be lost with the urine which is normally modulating the platelet response to AA. The observed increase in platelet affinity for AA could at least partially contribute to the enhanced thrombotic tendency reported in the same experimental model.

Keywords

Nephrotic syndrome - Platelet MDA - Albumi

• References

• 1 Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G, Donati MB. Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982; 46: 16-23
• 2 Poggi A, Komblihtt L, Delaini F, Colombo T, Mussoni L, Reyers I, Donati MB. Delayed hypercoagulability after a single dose of Adriamycin to normal rats. Thromb Res 1979; 16: 639-650
• 3 Yoshida N, Aoki N. Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 1978; 52: 969-977
• 4 Remuzzi G, Mecca G, Marchesi D, Livio M, de Gaetano G, Donati MB, Silver MJ. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979; 16: 345-354
• 5 Stuart MJ, Spitzer RE, Nelson DA, Sills RH. Nephrotic syndrome: Increased platelet prostaglandin endoperoxide formation, hyperaggregability, and reduced platelet life span. Reversal following remission. Pediatr Res 1980; 14: 1078-1081
• 6 Packham MA, Guccione MA, Greenberg JP, Kinlough-Rathbone RL, Mustard JF. Release of ¹⁴C-serotonin during initial platelet changes induced by thrombin, collagen, or A23187. Blood 1977; 50: 915-926
• 7 Villa S, Livio M, de Gaetano G. The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated. Br J Haematol 1979; 42: 425-431
• 8 Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 1976; 88: 167-172
• 9 de Gaetano G, Rajtar G, Livio M, Merino J. Arachidonic acid-induced malondialdehyde formation in rat platelets. Kinetic aspects and inhibition by acetylsalicylic acid and indomethacin. Naunyn Schmiedebergs Arch Pharmacol 1980; 312: 85-89
• 10 Dejana E, Barbieri B, Cerletti C, Livio M, de Gaetano G. Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats. Br J Haematol 1980; 46: 465-469
• 11 Lagarde M. Fatty acids bound to serum albumin potentiate platelet prostaglandin biosynthesis. Biochem Biophys Res Commun 1979; 88: 1346-1351
• 12 Dormandy TL. Free-radical oxidation and antioxidants. Lancet 1978; 1: 647-650